The convergent and divergent validity of the Matson Evaluation of Drug Side-effects (MEDS) and the Dyskinesia Identification System: Condensed User Scale (DISCUS)

References

• Advokat C. D., Mayville E. A., Matson J. L. Side-effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with intellectual disability. Research in Developmental Disabilities 2000; 21: 75–84
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders (4th ed.) – Text Revision. APA, Washington, DC 2000
   Google Scholar
• Borison R. L. Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. Journal of Clinical Psychopharmacology 1995; 15(Suppl. 1)24S–29S
   PubMed Web of Science ®Google Scholar
• Campbell D. T., Fiske D. W. Convergent and discriminant validation by the multitrait-multimethod matrix. Psychological Bulletin 1959; 56: 81–105
   PubMed Web of Science ®Google Scholar
• Campbell M., Young P. I., Bateman D. N., Smith J. M., Thomas S. H. L. The use of atypical antipsychotics in the management of schizophrenia. British Journal of Clinical Pharmacology 1999; 47(1)13–22
   PubMed Web of Science ®Google Scholar
• Fox R. A., Keller K. M., Grede P. L., Bartosz A. M. A mental health clinic for toddlers with developmental delays and behavior problems. Research in Developmental Disabilities 2007; 28: 119–129
   PubMed Web of Science ®Google Scholar
• Hove O. Survey on dysfunctional eating behavior in adult persons with intellectual disability living in the community. Research in Developmental Disabilities 2007; 28: 1–8
   PubMed Web of Science ®Google Scholar
• Kalachnik J. E., Sprague R. L., Slaw K. M. Training clinical personnel to assess for tardive dyskinesia. Progress in Neuropsychopharmacology & Biological Psychiatry 1988; 12: 749–762
   PubMed Web of Science ®Google Scholar
• Kampert A. C., Goreczny A. J. Community involvement and socialization among individuals with mental retardation. Research in Developmental Disabilities 2007; 28: 278–286
   PubMed Web of Science ®Google Scholar
• Kaushik S., Lindenmayer J. P., Khan A. Management of antipsychotic side effects. Primary Psychiatry 2007; 14: 77–82
   Google Scholar
• LeBlanc L. A., Geiger K. B., Sautter R. A., Sidener T. M. Using the Natural Language Paradigm (NLP) to increase vocalizations of older adults with cognitive impairments. Research in Developmental Disabilities 2007; 28: 437–444
   PubMed Web of Science ®Google Scholar
• Matson J. L. The Matson Evaluation of Social Skills for Individuals with Severe Retardation (MESSIER). Disability Consultants, LLC, Baton Rouge, LA 1995
   Google Scholar
• Matson J. L., Baglio C. S. Administrator's manual: Matson Evaluation of Drug Side Effects (MEDS). Scientific Publishers, Baton Rouge, LA 1998
   Google Scholar
• Matson J. L., Mayville E. A., Bielecki J., Barnes W. H., Bamburg J. W., Baglio C. S. Reliability of the Matson Evaluation of Drug Side-Effects scale (MEDS). Research in Developmental Disabilities 1998; 19: 501–506
   PubMed Web of Science ®Google Scholar
• Matson J. L., Mayville E. A., Bielecki J., Smalls Y., Eckholdt C. S. Tardive dyskinesia associated with metoclopramide in persons with developmental disabilities. Research in Developmental Disabilities 2002; 23: 224–233
   PubMed Web of Science ®Google Scholar
• Matson J. L., Minshawi N. F. Functional assessment of challenging behavior: Toward a strategy for applied settings. Research in Developmental Disabilities 2007; 28: 353–361
   PubMed Web of Science ®Google Scholar
• McGillivray J. A., McCabe M. P. Early detection of depression and associated risk factors in adults with mild/moderate intellectual disability. Research in Developmental Disabilities 2007; 28: 59–70
   PubMed Web of Science ®Google Scholar
• Miller C. H., Fleischhacker W. W. Managing antipsychotic-induced acute and chronic akathisia. Drug Safety 2000; 22: 73–81
   PubMed Web of Science ®Google Scholar
• Pierre J. M. Extrapyramidal symptoms with atypical antipsychotics: Incidence, prevention, and management. Drug Safety 2005; 28: 191–208
   PubMed Web of Science ®Google Scholar
• Plant K. M., Sanders M. R. Reducing problem behavior during care-giving in families of preschool-aged children with developmental disabilities. Research in Developmental Disabilities 2007; 28: 362–387
   PubMed Web of Science ®Google Scholar
• Ramirez S. Z., Lukenbill J. F. Development of the fear survey for adults with mental retardation. Research in Developmental Disabilities 2007; 28: 225–237
   PubMed Web of Science ®Google Scholar
• Richardson M. A., Haugland G., Pass R., Craig T. J. The prevalence of tardive dyskinesia in a mentally retarded population. Psychopharmacology Bulletin 1986; 22: 243–249
   PubMed Web of Science ®Google Scholar
• Rodnitzky R. L. Drug-induced movement disorders. Clinical Neuropharmacology 2002; 25: 142–152
   PubMed Web of Science ®Google Scholar
• Sparrow S., Balla D., Cicchetti D. V. The Vineland Adaptive Behavior Scales (Survey Form). American Guidance Service, Circle Pines, MN 1984
   Google Scholar
• Sprague R. L., Kalachnik J. E. Reliability, validity, and a total score cutoff for the Dyskinesia Identification System: Condensed User Scale (DISCUS) with mentally ill and mentally retarded populations. Psychopharmacology Bulletin 1991; 27: 51–58
   PubMed Web of Science ®Google Scholar
• Sprague R. L., Kalachnik J. E., White D. A. The Dyskinesia Identification System: Condensed User Scale (DISCUS). Institute for Child Behavior and Development, University of Illinois, Champaign, IL 1985
   Google Scholar
• Swanson J. M., Christian D. L., Wigal T., Clevenger W., Cavoto K. F., Ackerland V., et al. Tardive dyskinesia in a developmentally disabled population: Manifestation during the initial stage of a minimal effective dose program. Experimental and Clinical Psychopharmacology 1996; 4: 218–223
   Web of Science ®Google Scholar
• Wszola B. A., Newell K. M., Sprague R. L. Risk factors for tardive dyskinesia in a large population of youths and adults. Experimental and Clinical Psychopharmacology 2001; 9: 285–296
   PubMed Web of Science ®Google Scholar